Product Name:6-bromopyridin-2-amine

IUPAC Name:6-bromopyridin-2-amine

CAS:19798-81-3
Molecular Formula:C5H5BrN2
Purity:98%
Catalog Number:CM101911
Molecular Weight:173.01

Packing Unit Available Stock Price($) Quantity
CM101911-100g in stock ȀƄ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:19798-81-3
Molecular Formula:C5H5BrN2
Melting Point:-
Smiles Code:NC1=NC(Br)=CC=C1
Density:
Catalog Number:CM101911
Molecular Weight:173.01
Boiling Point:272.9°C at 760 mmHg
MDL No:MFCD00137843
Storage:Keep in dark place, store at 2-8°C.

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Voydeya
Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). Voydeya is the first drug in the class to be cleared for marketing anywhere in the world and has been licensed for use as an add-on therapy to C5 inhibitors, like its own Soliris (eculizumab) and Ultomiris (ravulizumab) products, in patients who don’t get a satisfactory response from C5 drugs alone. Voydeya (danicopan) is a first-in-class oral Factor D inhibitor. Voydeya has been granted Breakthrough Therapy designation by the US Food and Drug Administration and PRIority MEdicines (PRIME) status by the European Medicines Agency. Voydeya has also been granted Orphan Drug Designation in the US, EU and Japan for the treatment of PNH.